Hydrocortisone succinate
- Generic Name
- Hydrocortisone succinate
- Brand Names
- Solu-cortef
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O8
- CAS Number
- 2203-97-6
- Unique Ingredient Identifier
- IHV1VP592V
- Associated Conditions
- Acquired hemolytic anemias, Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia, Idiopathic Nephrotic Syndrome, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Mycosis Fungoides (MF), Ocular Inflammatory Disease, Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Proteinuria, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Severe Allergic Reactions, Severe Erythema multiforme, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02096510
- Locations
- 🇳🇴
University Hospital Helse Bergen, Bergen, Norway
Prospective Randomized Study of Glucocorticoids in the Impact of the Liver Function and the Prognosis After Hepatectomy of HCC
Suspended
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01608945
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2
- Conditions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 180
- Registration Number
- NCT01005758
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideBiological: FilgrastimDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: PrednisoneRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00720109
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
ALL Adult Consortium Trial: Adult ALL Trial
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
Corticosteroid Therapy of Septic Shock - Corticus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 500
- Registration Number
- NCT00147004
- Locations
- 🇦🇹
Universitaetsklinik fuer Innere Medizin II, Wien, Austria
🇧🇪Hopital St. Joseph, Arlon, Belgium
🇧🇪Cliniques Universitaires St. Luc, UCL, Brussels, Belgium
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Phase 2
Completed
- Conditions
- Childhood Immunoblastic Large Cell LymphomaChildhood Diffuse Large Cell LymphomaStage I Childhood Small Noncleaved Cell LymphomaStage II Childhood Large Cell LymphomaStage II Childhood Small Noncleaved Cell LymphomaStage IV Childhood Small Noncleaved Cell LymphomaStage I Childhood Large Cell LymphomaStage III Childhood Large Cell LymphomaStage IV Childhood Large Cell LymphomaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: methotrexateDrug: leucovorin calciumDrug: rasburicaseDrug: prednisoneDrug: methylprednisoloneBiological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: vincristine sulfateDrug: hydrocortisone sodium succinateOther: laboratory biomarker analysis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00057811
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath